Daily Stock Analysis, HZNP, Horizon Pharma PLC, priceseries

Horizon Pharma PLC. Daily Stock Analysis
Stock Information
Open
26.52
Close
27.21
High
27.44
Low
26.46
Previous Close
26.50
Daily Price Gain
0.71
YTD High
29.44
YTD High Date
Feb 28, 2019
YTD Low
19.23
YTD Low Date
Jan 2, 2019
YTD Price Change
7.28
YTD Gain
36.53%
52 Week High
29.44
52 Week High Date
Feb 28, 2019
52 Week Low
16.56
52 Week Low Date
Oct 26, 2018
52 Week Price Change
8.39
52 Week Gain
44.58%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
10.84
Jul 27. 2017
12.82
26 Trading Days
18.28%
Link
LONG
Sep 27. 2017
12.51
Oct 16. 2017
13.61
13 Trading Days
8.79%
Link
LONG
Feb 28. 2018
14.58
Mar 13. 2018
15.34
9 Trading Days
5.21%
Link
LONG
May 11. 2018
14.25
Jun 25. 2018
17.18
30 Trading Days
20.57%
Link
LONG
Aug 7. 2018
18.16
Aug 23. 2018
19.98
12 Trading Days
10.01%
Link
LONG
Jan 31. 2019
21.49
Feb 19. 2019
22.80
12 Trading Days
6.11%
Link
Company Information
Stock Symbol
HZNP
Exchange
NasdaqGS
Company URL
http://www.horizonpharma.com
Company Phone
011-353-1-772-2100
CEO
Timothy P. Walbert
Headquarters
-
Business Address
CONNAUGHT HOUSE, 1ST FLOOR, 1 BURLINGTON ROAD, DUBLIN, IRELAND 4
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001492426
About

Horizon Pharma Plc engages in the research, development, and market of pharmaceutical products. Its medicines intend to treat arthritis, inflammation, and orphan diseases. It distributes under the following brands: Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos, and Vimovo. The company was founded on December 20, 2011 and is headquartered in Dublin, Ireland.

Description

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.